SCHEMBL1630102

SCHEMBL1630102

NC(=O)C(c1cccnc1)c1ccc(-c2ccccc2)nc1NCCc1cccc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 2/20 0.44
CSNK2A1 P68400 2/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
GAA P10253 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
LCK P06239 1/20 0.41
HIF1A Q16665 1/20 0.40
ACP1 P24666 1/20 0.40
GBA1 P04062 2/20 0.39
TRPM8 Q7Z2W7 2/20 0.39
JAK3 P52333 1/20 0.39
MAPT P10636 3/20 0.39
THRB P10828 1/20 0.39
ALDH1A1 P00352 2/20 0.38
ABL1 P00519 1/20 0.38
SRC P12931 1/20 0.38
HDAC3 O15379 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1631443 0.91 NPC1 (0.45) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL1630219 0.91 EP300 (0.42) SMN1; SMN2NPC1RAB9AGBA1MAPT
SCHEMBL1631415 0.90 GBA1 (0.45) MEN1KMT2ASMN1; SMN2GAANPC1
SCHEMBL1632043 0.90 ALDH1A1 (0.40) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL1631787 0.90 GBA1 (0.51) CSNK2A2CSNK2A1MEN1KMT2ASMN1; SMN2
SCHEMBL1629879 0.88 GBA1 (0.39) SMN1; SMN2NPC1RAB9AGBA1MAPT
SCHEMBL1632284 0.88 CSNK2A2 (0.46) CSNK2A2CSNK2A1MEN1KMT2ASMN1; SMN2
SCHEMBL4120643 0.88 ALDH1A1 (0.42) MEN1KMT2AGBA1TRPM8JAK3
SCHEMBL1630481 0.88 CYP3A4 (0.41) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL1631828 0.86 GBA1 (0.42) CSNK2A2CSNK2A1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 US claimed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012126-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 CSNK2A2 595/4885CSNK2A1 835/4885MEN1 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.